newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C